Population Pharmacokinetics and Exposure — Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Xiaoli Wang(Shenyang Pharmaceutical University), Matthew Hruska(Bristol-Myers Squibb (United States)), Akintunde Bello(Bristol-Myers Squibb (United States)), Julie Passarell(Cognizant (United States)), Elizabeth Ludwig(Cognizant (United States)), Amit Roy(Bristol-Myers Squibb (United States))
The Journal of Clinical Pharmacology
October 19, 2018
Cited by 17


Related Papers